ecteribulin
Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization
Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin
Actionable Insights Powered by AI
Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin